AAAAAA

   
Results: 1-12 |
Results: 12
Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition
Authors: Dechend, R Fiebler, A Lindschau, C Bischoff, H Muller, D Park, JK Dietz, R Haller, H Luft, FC
Citation: R. Dechend et al., Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition, AM J HYPERT, 14(6), 2001, pp. 55S-61S
Main achievements of FP-4 research in reactor safety
Authors: Van Goethem, G Zurita, A Bermejo, JM Lemaitre, P Bischoff, H
Citation: G. Van Goethem et al., Main achievements of FP-4 research in reactor safety, NUCL ENG DE, 209(1-3), 2001, pp. 29-37
Combinatorial synthesis of cholesterol ester transfer protein-mRNA ligandsand screening by nondenaturating gel-electrophoresis
Authors: Baumann, M Bischoff, H Schmidt, D Griesinger, C
Citation: M. Baumann et al., Combinatorial synthesis of cholesterol ester transfer protein-mRNA ligandsand screening by nondenaturating gel-electrophoresis, J MED CHEM, 44(13), 2001, pp. 2172-2177
Enzyme-catalyzed condensation reaction in a mammalian alpha-amylase. High-resolution structural analysis of an enzyme-inhibitor complex
Authors: Qian, MX Nahoum, V Bonicel, J Bischoff, H Henrissat, B Payan, F
Citation: Mx. Qian et al., Enzyme-catalyzed condensation reaction in a mammalian alpha-amylase. High-resolution structural analysis of an enzyme-inhibitor complex, BIOCHEM, 40(25), 2001, pp. 7700-7709
Untitled
Authors: Bischoff, H
Citation: H. Bischoff, Untitled, IEEE ELEC I, 16(4), 2000, pp. 5-5
Crystal structures of human pancreatic alpha-amylase in complex with carbohydrate and proteinaceous inhibitors
Authors: Nahoum, V Roux, G Anton, V Rouge, P Puigserver, A Bischoff, H Henrissat, B Payan, F
Citation: V. Nahoum et al., Crystal structures of human pancreatic alpha-amylase in complex with carbohydrate and proteinaceous inhibitors, BIOCHEM J, 346, 2000, pp. 201-208
The fourth framework programme summarised
Authors: van Geothem, G Bermejo, JM Zurita, A Bischoff, H Lemaitre, P
Citation: G. Van Geothem et al., The fourth framework programme summarised, NUCL ENG IN, 45(550), 2000, pp. 25-27
Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate
Authors: Oikonomakos, NG Tsitsanou, KE Zographos, SE Skamnaki, VT Goldmann, S Bischoff, H
Citation: Ng. Oikonomakos et al., Allosteric inhibition of glycogen phosphorylase a by the potential antidiabetic drug 3-isopropyl 4-(2-chlorophenyl)-1,4-dihydro-1-ethyl-2-methyl-pyridine-3,5,6-tricarboxylate, PROTEIN SCI, 8(10), 1999, pp. 1930-1945
Type I osteogenesis imperfecta: Diagnostic difficulties
Authors: Bischoff, H Freitag, P Jundt, G Steinmann, B Tyndall, A Theiler, R
Citation: H. Bischoff et al., Type I osteogenesis imperfecta: Diagnostic difficulties, CLIN RHEUMA, 18(1), 1999, pp. 48-51
Immobility as a major cause of bone remodeling in residents of a long-staygeriatric ward
Authors: Bischoff, H Stahelin, HB Vogt, P Friderich, P Vonthein, R Tyndall, A Theiler, R
Citation: H. Bischoff et al., Immobility as a major cause of bone remodeling in residents of a long-staygeriatric ward, CALCIF TIS, 64(6), 1999, pp. 485-489
BEACOPP: A new regimen for advanced Hodgkin's disease
Authors: Diehl, V Franklin, J Hasenclever, D Tesch, H Pfreundschuh, M Lathan, B Paulus, U Sieber, M Ruffer, JU Sextro, M Engert, A Wolf, J Hermann, R Holmer, L Stappert-Jahn, U Winnerlein-Trump, E Wulf, G Krause, S Glunz, A von Kalle, K Bischoff, H Haedicke, C Duhmke, E Georgii, A Loeffler, M
Citation: V. Diehl et al., BEACOPP: A new regimen for advanced Hodgkin's disease, ANN ONCOL, 9, 1998, pp. 67-71
BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group
Authors: Diehl, V Franklin, J Hasenclever, D Tesch, H Pfreundschuh, M Lathan, B Paulus, U Sieber, M Rueffer, JU Sextro, M Engert, A Wolf, J Hermann, R Holmer, L Stappert-Jahn, U Winnerlein-Trump, E Wulf, G Krause, S Glunz, A von Kalle, K Bischoff, H Haedicke, C Duehmke, E Georgii, A Loeffler, M
Citation: V. Diehl et al., BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: Interim report from a trial of the German Hodgkin's Lymphoma Study Group, J CL ONCOL, 16(12), 1998, pp. 3810-3821
Risultati: 1-12 |